Financial Performance - The company's operating revenue for Q1 2022 was ¥1,176,098,332.11, representing a year-on-year increase of 2.96%[7] - The net profit attributable to shareholders was ¥200,394,843.05, reflecting an increase of 8.26% compared to the same period last year[7] - Total operating revenue for Q1 2022 was RMB 1,176,098,332.11, an increase of 2.5% compared to RMB 1,142,265,947.08 in Q1 2021[28] - Net profit for Q1 2022 reached RMB 200,306,762.89, representing a 8.4% increase from RMB 185,359,261.72 in Q1 2021[30] - Earnings per share for Q1 2022 was RMB 0.36, unchanged from Q1 2021[30] Cash Flow - The net cash flow from operating activities surged by 283.08%, amounting to ¥68,528,706.19, primarily due to increased tax refunds and reduced payments for other operating activities[9] - Cash flow from operating activities for Q1 2022 was RMB 68,528,706.19, significantly higher than RMB 17,888,722.47 in Q1 2021[33] - Net cash inflow from investment activities amounted to ¥1,162,429,657.10, a significant increase compared to ¥2,333,333.73 from the previous period[36] - Cash outflow from investment activities totaled ¥1,188,099,278.00, compared to ¥150,248,614.93 in the prior period, resulting in a net cash flow from investment activities of -¥25,669,620.90, an improvement from -¥147,915,281.20[36] - The net increase in cash and cash equivalents was ¥70,261,999.34, contrasting with a decrease of -¥292,551,015.14 in the prior period[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,759,156,783.71, up 3.28% from the previous year[9] - Total liabilities as of March 31, 2022, were RMB 1,213,156,316.00, compared to RMB 1,167,378,598.11 at the end of 2021, reflecting an increase of about 3.9%[23] - The company's cash and cash equivalents stood at RMB 910,106,181.01, up from RMB 893,006,462.03, indicating a growth of about 1.24%[19] - Accounts receivable increased to RMB 579,134,299.55 from RMB 445,030,444.75, representing a significant rise of approximately 30.1%[19] - Inventory levels rose to RMB 1,408,703,582.09, compared to RMB 1,309,329,113.87, marking an increase of around 7.6%[19] Shareholder Information - The company had a total of 37,071 common shareholders at the end of the reporting period[13] - Major shareholders included Xinchang Ander Trading Co., Ltd. with a 23.08% stake and Xinchang Qingyu Investment Development Co. with a 13.12% stake[13] Equity and Returns - The equity attributable to shareholders increased by 3.16% to ¥6,546,474,291.86 compared to the end of the previous year[9] - The weighted average return on equity decreased by 2.39 percentage points to 3.11%[7] - The company's equity attributable to shareholders reached RMB 6,546,474,291.86, up from RMB 6,346,079,448.81, indicating a growth of approximately 3.15%[23] Expenses - Research and development expenses for Q1 2022 were RMB 31,655,326.74, slightly down from RMB 32,962,901.43 in Q1 2021[28] - Management expenses increased to RMB 65,252,836.36 in Q1 2022 from RMB 55,745,345.68 in Q1 2021, marking a rise of 17%[28] - Financial expenses decreased significantly to RMB 831,313.77 in Q1 2022 from RMB 5,159,934.36 in Q1 2021[28] - The company reported an investment income of RMB 6,011,137.92 in Q1 2022, a recovery from a loss of RMB 445,438.00 in Q1 2021[28]

Financial Performance - The company's operating revenue for 2021 was CNY 4.505 billion, an increase of 7.11% compared to CNY 4.206 billion in 2020[26]. - The net profit attributable to shareholders for 2021 was CNY 706 million, a decrease of 12.84% from CNY 810 million in 2020[26]. - The net cash flow from operating activities for 2021 was negative CNY 176 million, a decrease of 122.95% compared to CNY 767 million in 2020[26]. - The total assets increased by 36.39% to CNY 7.513 billion in 2021 from CNY 5.509 billion in 2020[27]. - The net assets attributable to shareholders increased by 93.79% to CNY 6.346 billion in 2021 from CNY 3.275 billion in 2020[27]. - The basic earnings per share for 2021 was CNY 1.38, a decrease of 19.30% from CNY 1.71 in 2020[26]. - The company achieved operating revenue of 4,505.35 million RMB, an increase of 7.11% compared to the same period last year[79]. - Operating costs amounted to 3,147.62 million RMB, reflecting a 13.39% increase year-on-year[81]. - The net profit attributable to the parent company was 706.03 million RMB, a decrease of 12.84% compared to the previous year[79]. - Research and development expenses increased to 155.27 million RMB, up 13.18% from the previous year[81]. Risk Management and Governance - The company has confirmed that there are no significant risks that could materially affect its operations during the reporting period[9]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[9]. - The company has outlined potential risk factors and countermeasures in its management discussion and analysis section[9]. - There are no violations of decision-making procedures regarding external guarantees during the reporting period[9]. - The company has established a governance structure that complies with legal requirements, ensuring independent operation of the board of directors and supervisory board, with no non-operational occupation of funds by controlling shareholders[166]. - The company has implemented a risk management mechanism to monitor foreign exchange rate changes and employs forward foreign exchange contracts to minimize risks associated with currency fluctuations[164]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company’s financial report has been declared to be true, accurate, and complete by its responsible persons and accounting heads[6]. - The company confirmed the internal control self-assessment report and the implementation of related party transactions for 2020, along with expected transactions for 2021[198]. - The Audit Committee held 4 meetings during the reporting period, reviewing key financial reports and confirming the appointment of the auditing firm for 2021[198]. Research and Development - The company invested 1.55 million CNY in R&D in 2021, accounting for 3.45% of its total revenue, and received 34 patent applications during the year[42]. - The company has 50 controlled R&D projects, with 9 collaborative projects, indicating a strong focus on innovation and research[42]. - The company applied for 34 patents during the reporting period and received 17 authorized patents, all of which are invention patents[123]. - The company's R&D investment amounted to 47,921.63 million RMB, representing 5.36% of operating revenue and 9.47% of net assets[131]. - The company has increased R&D investment and is forming a reasonable R&D team through recruitment and training, ensuring leading R&D work and developing a gradient of R&D and reserve projects[160]. Market and Product Strategy - The company implemented a product strategy focusing on multi-variety replication and appropriate extension of the industrial chain[38]. - The company aims to enhance its global market presence and product offerings, continuing to develop high-value and high-growth products by 2025[47]. - The company is actively pursuing market expansion in developing countries, particularly in Southeast Asia and Africa, leveraging its product quality and competitive pricing[70]. - The company has established a sales network covering 115 countries and regions, with over 3,000 customers globally[70]. - The company is focused on expanding its market presence and enhancing its product offerings through new technology development[179]. Environmental and Safety Investments - The company’s safety and environmental protection investments totaled 216 million CNY in 2021, emphasizing its commitment to sustainable development[45]. - The company is committed to environmental protection and has increased investments in green production in response to stricter regulations and policies related to carbon neutrality[162]. Shareholder and Executive Compensation - The total pre-tax compensation for all directors and supervisors during the reporting period amounted to 16.1075 million yuan[177]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 16.1075 million yuan[188]. - The total number of shares held by the chairman, Qiu Jiajun, remained unchanged at 54,852,971 shares, with a pre-tax compensation of 2.1486 million yuan for the reporting period[177]. - The total number of shares held by director Zhu Yaqing remained unchanged at 7,452,666 shares, with a pre-tax compensation of 1.7552 million yuan for the reporting period[177]. - The total number of shares held by the vice president, Lv Fangfang, remained unchanged at 1,740,302 shares, with a pre-tax compensation of 2.0683 million yuan for the reporting period[177]. Production and Capacity Expansion - The company is expanding its production capacity with a new project to produce 40,000 tons of liquid sodium borohydride annually, enhancing its supply capabilities significantly[52]. - The company has established modern production bases in two national industrial parks, achieving international certifications including FDA and EUGMP[51]. - The company has over 2,450 acres of factory land across three bases, with significant development space in national industrial parks[62]. - The company has successfully completed the trial production of the first phase of the strong streptomycin project, which is expected to become one of the major products in the future[53]. Sales and Revenue Breakdown - The pharmaceutical segment reported revenue of ¥2,959,421,609.16 with a gross margin of 30.25%, a decrease of 6.58 percentage points year-over-year[1]. - The animal health segment achieved revenue of ¥1,533,498,778.87, with a gross margin of 29.49%, an increase of 2.29 percentage points year-over-year[1]. - The revenue from domestic sales was ¥2,598,318,091.57, with a gross margin of 31.96%, reflecting a decrease of 0.86 percentage points year-over-year[1]. - The revenue from overseas sales was ¥1,894,602,296.46, with a gross margin of 27.28%, a decrease of 7.92 percentage points year-over-year[1].

Financial Performance - Q3 2021 revenue was CNY 970,805,310.32, a decrease of 4.34% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 143,392,791.45, down 24.78% year-over-year[5] - Basic earnings per share decreased by 32.50% to CNY 0.27[5] - Total revenue for the first three quarters of 2021 reached ¥3,213,201,476.59, an increase from ¥3,146,413,574.55 in the same period of 2020, representing a growth of approximately 2.1%[22] - Net profit for the third quarter of 2021 was ¥521,648,888.67, down from ¥637,566,383.83 in the same quarter of 2020, reflecting a decrease of approximately 18.2%[24] - The total comprehensive income attributable to the parent company for Q3 2021 was CNY 521,083,615.73, compared to CNY 637,255,433.23 in Q3 2020, representing a decrease of approximately 18.3%[26] - The basic and diluted earnings per share for Q3 2021 were both CNY 1.06, down from CNY 1.34 in Q3 2020, indicating a decline of about 20.9%[26] Assets and Liabilities - Total assets increased by 39.98% to CNY 7,710,988,911.71 compared to the end of the previous year[6] - Total current assets as of September 30, 2021, reached RMB 4,892,042,697.18, an increase from RMB 2,871,167,094.62 in the previous year[17] - The company’s total non-current assets were valued at RMB 2,835,000,000.00 as of September 30, 2021, compared to RMB 2,700,000,000.00 at the end of 2020[17] - The company’s total liabilities as of September 30, 2021, were RMB 3,500,000,000.00, reflecting a stable financial position[17] - The total liabilities decreased to ¥1,270,464,118.84 in Q3 2021 from ¥2,234,426,905.61 in Q3 2020, a reduction of approximately 43.2%[21] - The equity attributable to shareholders rose by 96.67% to CNY 6,440,544,494.22 compared to the end of the previous year[6] - The equity attributable to shareholders increased to ¥6,440,544,494.22 in Q3 2021 from ¥3,274,732,831.94 in Q3 2020, representing an increase of about 96.5%[21] Cash Flow - Cash flow from operating activities showed a significant decline of 107.44% year-to-date, resulting in a net outflow of CNY -50,481,356.46[5][8] - Cash inflow from operating activities for the first nine months of 2021 was CNY 1,799,024,987.26, compared to CNY 1,722,182,333.11 in the same period of 2020, reflecting an increase of approximately 4.5%[28] - The net cash flow from operating activities for the first nine months of 2021 was negative CNY 50,481,356.46, contrasting with a positive CNY 678,440,784.53 in the same period of 2020[28] - Cash inflow from investment activities for the first nine months of 2021 was CNY 1,196,583,611.02, significantly higher than CNY 507,948,250.33 in the same period of 2020, marking an increase of approximately 135.5%[29] - The net cash flow from investment activities for the first nine months of 2021 was negative CNY 1,467,101,349.96, compared to negative CNY 260,252,373.92 in the same period of 2020[29] - Cash inflow from financing activities for the first nine months of 2021 was CNY 2,938,582,578.68, compared to CNY 414,652,518.90 in the same period of 2020, indicating a substantial increase[29] - The net cash flow from financing activities for the first nine months of 2021 was CNY 1,930,678,325.30, contrasting with a negative CNY 254,082,367.15 in the same period of 2020[29] - The ending cash and cash equivalents balance as of the end of Q3 2021 was CNY 1,288,226,413.62, up from CNY 949,014,136.59 at the end of Q3 2020, representing an increase of approximately 35.7%[29] Shareholder Information - The company announced an automatic extension of the lock-up period for major shareholders by 6 months due to stock price conditions[14] - The company’s major shareholders include New Chang Ande Trading Co., Ltd., holding 23.08% of shares, and New Chang Qingyu Investment Development Co., Ltd., holding 13.12%[12] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥2,605,167,043.75, compared to ¥2,396,549,043.76 in 2020, indicating an increase of about 8.7%[22] - Research and development expenses for the first three quarters of 2021 were ¥106,211,901.82, compared to ¥96,927,165.16 in 2020, showing an increase of approximately 9.2%[22] - Financial expenses decreased significantly to ¥20,810,750.92 in Q3 2021 from ¥49,949,183.20 in Q3 2020, a reduction of about 58.3%[24] - The company reported a decrease in short-term borrowings to ¥235,242,905.56 in Q3 2021 from ¥509,407,335.28 in Q3 2020, a decline of approximately 53.8%[20] Return on Equity - The weighted average return on equity decreased by 3.73 percentage points to 2.61%[5] - The total liabilities to equity ratio improved significantly, indicating a stronger financial position for the company in Q3 2021 compared to Q3 2020[21]